Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Eversheds Sutherland has continued its expansion in the US, with the opening of a San Diego office and the addition of three IP litigators.
The US Patent and Trademark Office has granted Mammoth Biosciences applications for two patents covering what the company claims are “first-of-their-kind” CRISPR diagnostic techniques.
Hong Kong customs authorities have carried out a series of raids resulting in the seizure of counterfeit vaccines worth over HKD $1 million, some containing poison.
Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.
Massachusetts-based medical laser company Candela and Israeli medical devices manufacturer Lumenis have settled all outstanding patent litigation between the two parties.
India’s Delhi High Court has dismissed a petition for an injunction by German pharma company Bayer against an Indian competitor.
Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.